Plant Name: Ligusticum jeholense
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.744E-11 | 5.432E-08 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 5.157E-10 | 7.486E-07 | CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 9.011E-10 | 1.226E-06 | CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.893E-08 | 1.718E-05 | CA1, CA12, CA2, CA5A, CA6, CA7, CA9, PPARA, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.498E-08 | 2.539E-05 | ALOX15, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 2.661E-07 | 1.436E-04 | FFAR4, NFKB1, PPARA, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.639E-07 | 1.436E-04 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.681E-07 | 1.864E-04 | CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 4.566E-07 | 2.161E-04 | CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, PPARD |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.539E-07 | 2.161E-04 | CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 8.063E-07 | 3.583E-04 | CA2, CA9, FABP3, FFAR4, HPGD, NFKB1, PPARA, PPARG |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 1.133E-06 | 4.744E-04 | CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 1.333E-06 | 5.278E-04 | FABP3, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.209E-06 | 8.292E-04 | CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 4.435E-06 | 1.583E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.435E-06 | 1.583E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0016712; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | 4.300E-06 | 1.583E-03 | CYP2A6, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 8.864E-06 | 2.924E-03 | CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.116E-05 | 3.574E-03 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 1.476E-05 | 4.464E-03 | PPARA, PPARG |
| BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 2.213E-05 | 5.805E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0010871; negative regulation of receptor biosynthetic process | 2.213E-05 | 5.805E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 2.213E-05 | 5.805E-03 | ALOX15, HPGD |
| MF | GO:0005488; binding | GO:0050543; icosatetraenoic acid binding | 2.213E-05 | 5.805E-03 | FABP3, PPARG |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 2.213E-05 | 5.805E-03 | CA1, CA2 |
| BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 2.921E-05 | 7.482E-03 | ACHE, CYP3A4, FFAR1, FFAR4, NFKB1, PPARD |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 2.991E-05 | 7.485E-03 | PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 3.095E-05 | 7.489E-03 | CYP2A6, CYP2D6 |
| BP | GO:0051179; localization | GO:0051049; regulation of transport | 3.714E-05 | 8.790E-03 | ACHE, ALOX15, CA2, CA7, FFAR1, FFAR4, NFKB1, PPARA, PPARD, PPARG |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 9.810E-21 | 2.136E-16 | CA1, CA12, CA14, CA2, CA5A, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.645E-16 | 2.880E-12 | CA1, CA12, CA14, CA2, CA5A, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.421E-14 | 5.156E-11 | CA1, CA12, CA2, CA5A, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.802E-20 | 2.270E-18 | CA12; CA1; CA2; CA5A; CA7; CA6; CA9; CA14 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.704E-08 | 6.899E-07 | CYP2C9; CYP2A6; CYP2D6; CYP3A4; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.712E-08 | 1.002E-06 | CYP2C9; ALOX15; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.642E-06 | 2.660E-05 | CYP2C9; CYP2A6; CYP2D6; CYP3A4 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.308E-06 | 2.650E-05 | FABP3; PPARG; PPARA; PPARD |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 9.082E-06 | 1.051E-04 | CYP2C9; CYP2D6; ALOX15; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.620E-06 | 3.537E-05 | CYP2C9; CYP2A6; CYP3A4; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 5.481E-05 | 5.550E-04 | CYP2C9; ALOX15; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 6.316E-05 | 5.684E-04 | CYP2C9; CYP2A6; CYP3A4 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.263E-03 | 1.018E-02 | HPGD; PPARG; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.116E-03 | 1.428E-02 | NFKB1; PPARD |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.383E-03 | 1.018E-02 | CYP2A6; CYP3A4 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 3.171E-03 | 1.886E-02 | PPARA; NFKB1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 5.640E-03 | 3.031E-02 | PPARG; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.260E-03 | 1.886E-02 | CA2; CYP3A4 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.153E-02 | 4.670E-02 | PPARG; NFKB1; PPARD |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 7.512E-03 | 3.579E-02 | PPARA; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.085E-02 | 4.670E-02 | PPARG; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.214E-02 | 4.682E-02 | LMNA; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.101E-02 | 4.670E-02 | PPARA; NFKB1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 5.986E-03 | 3.031E-02 | CYP2A6 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; NFKB1; PPARD; PPARG; PPARG |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE; PPARG; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA1; CA9; NFKB1; ACHE |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PPARG |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; ACHE |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; PPARG |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |